| Title |
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
|
|---|---|
| Published in |
Targeted Oncology, November 2011
|
| DOI | 10.1007/s11523-011-0201-x |
| Pubmed ID | |
| Authors |
Camille Tlemsani, Olivier Mir, Pascaline Boudou-Rouquette, Olivier Huillard, Karin Maley, Stanislas Ropert, Romain Coriat, François Goldwasser |
| Abstract |
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Unknown | 57 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 19% |
| Other | 10 | 17% |
| Student > Master | 7 | 12% |
| Student > Postgraduate | 5 | 9% |
| Student > Ph. D. Student | 3 | 5% |
| Other | 9 | 16% |
| Unknown | 13 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 52% |
| Neuroscience | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Economics, Econometrics and Finance | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 2 | 3% |
| Unknown | 17 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2011.
All research outputs
#20,150,151
of 22,656,971 outputs
Outputs from Targeted Oncology
#505
of 546 outputs
Outputs of similar age
#217,234
of 238,843 outputs
Outputs of similar age from Targeted Oncology
#2
of 4 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 546 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,843 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.